Authors


Sara Pavitt, MD

Latest:

Using a Novel Educational Intervention to Improve Overall Knowledge of Headache: Sara Pavitt, MD

The chief of headache at UT Austin Dell Children’s Hospital provided insight on a new series designed to deliver longitudinal comprehensive pediatric headache education. [WATCH TIME: 3 minutes]


Jessica Caldwell, PhD

Latest:

The Realities of Gender-Targeted Therapeutics for Alzheimer Disease: Jessica Caldwell, PhD

The director of the Women’s Alzheimer’s Movement Preventer Center at Cleveland Clinic provided perspective on the possibility of gender-specific therapies to overcome disparities in Alzheimer disease. [WATCH TIME: 3 minutes]


Jason M. Davies, MD, PhD

Latest:

The Potential of Embolization as a Treatment Approach for Subdural Hematomas: Jason M. Davies, MD, PhD

The assistant professor of neurosurgery and biomedical informatics at the State University of New York at Buffalo talked about the efficacy and safety of using embolization as a promising treatment for subdural hematomas. [WATCH TIME: 3 minutes]


Ahmed Obeidat, MD, PhD

Latest:

Anti-CD20 Therapies for MS

Ahmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, talk about the factors to consider when determining whether patients are candidates for anti-CD20 therapies.


Cathleen M. Lutz, PhD

Latest:

Understanding Stathmin-2’s Impact on ALS Motor and Sensory Denervation: Cathleen M. Lutz, PhD

The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]


Paul G. Mathew, MD, DNPAS, FAAN, FAHS

Latest:

Building the Next Generation of Migraine Specialists: Rashmi B. Halker-Singh, MD, FAAN, and Paul Mathew, MD, DNBPAS, FAAN, FAHS

The chair and vice-chair of the Headache and Facial Pain Section of the American Academy of Neurology provided insight on projects they feel are needed to advance the care of patients with migraine-related disorders. [WATCH TIME: 4 minutes]


Amy Kunchok, MD, PhD

Latest:

Real-World Effectiveness and Safety of Monoclonal Antibodies in NMOSD: Amy Kunchok, MD, PhD

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]


Duren M. Ready, MD, FAHS

Latest:

Building Your Acute Migraine Toolbox

Plagued by a long history of under- and inadequate treatment, clinicians have more options than ever to craft a personalized, effective plan for their patients.


Christopher A. Scheiner, MD, PhD

Latest:

Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]


Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI

Latest:

Occurrence of Late-Onset Neurotropenia After Anti-CD20 Therapy: Tianrong Yeo, PhD, MBBS, MRCP, MMED, FAMS, MCI

The senior consultant for the department of neurology at the National Neuroscience Institute discussed a report on two patients who developed an uncommon adverse event of late-onset neurotropenia after anti-CD20 therapy treatment. [WATCH TIME: 8 minutes]


Irene Wang, PhD

Latest:

How MR Fingerprinting Can Improve Epilepsy Surgery: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting. [WATCH TIME: 3 minutes]


Jim Cassidy, MD, PhD

Latest:

Potential of Advancing Neurofibromatosis Care With Investigational Mirdametinib

Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization of mirdametinib, a promising treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.


James E. Galvin, MD, MPH

Latest:

Expanding the Pathways to Treat Dementia With Lewy Bodies: James Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine detailed the need for improved biomarkers of dementia with Lewy bodies and whether research in Alzheimer disease helps propel the field. [WATCH TIME: 3 minutes]


Lloyd Tran, PhD

Latest:

Therapeutic Potential of Combination Strategies to Treat Alzheimer Disease: Lloyd Tran, PhD

The chairman and chief executive officer at Biomed discussed the additive benefits of combination therapy for Alzheimer disease, providing context on the strengths of different drugs and how it might lead to a more precision medicine approach. [WATCH TIME: 6 minutes]


John F. Crary, MD, PhD

Latest:

The Future of Digital Neuropathology and the Role of AI: John F. Crary, MD, PhD; Gerardo Fernandez, MD

The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]


John Greenfield, MD, PhD

Latest:

AI in Academic Neurology: A Chat With ChatGPT-4

L. John Greenfield Jr, MD, PhD, “spoke” about the future of artificial intelligence in neurology with ChatGPT-4—one of the largest language modules that have grabbed the field’s interest.


Cathleen Lutz, PhD

Latest:

Steps to Validate Stathmin-2 as an ALS-Specific Biomarker: Cathleen Lutz, PhD

The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]


Lauren Gluck, MD

Latest:

Challenges of Shared Decision-Making in the Management of Multiple Sclerosis

Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.


Anita Shelgikar, MD, MHPE

Latest:

The Importance of Sleep Medicine Education: Anita Shelgikar, MD, MHPE

The clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]


This is where the author name appears

Latest:

SPONSORED ARTICLE TEMPLATE

This is the deck of the article. It can be used to provide further context to the headline and provides search engines with summary text for social posts.


Deena Kuruvilla, MD

Latest:

The Mini-Prevention Concept in Migraine Care: Deena Kuruvilla, MD

The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine


Thomas F. Scott, MD

Latest:

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]


Emily Harrington, MD, PhD

Latest:

Tackling Neurodegeneration in Multiple Sclerosis: Emily Harrington, MD, PhD

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]


Lawrence Steinman, MD

Latest:

Evolution of Anti-CD20 Disease Modifying Therapies in Multiple Sclerosis - Recent Updates

In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.


Teri Schreiner, MD

Latest:

Balancing COVID-19 Infection Risk and Disease Control in Pediatric Onset MS: Teri Schreiner, MD

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]


Caroline Just, MD, FRCPC, CSC-EEG

Latest:

Rare Diseases Are More Common Than Their Name May Imply

Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.


Adel M. Malek, MD, PhD

Latest:

A New Approach to Communicating Hydrocephalus: An Overdue Opportunity

A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.


Ruth Ann Marrie, MD, PhD, FRCPC

Latest:

Future Implications of New Framework to Characterize Multiple Sclerosis: Ruth Ann Marrie, MD, PhD, FRCPC

The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]


David T. Jones, MD

Latest:

Implementing New Diagnostic Criteria of Limbic-Predominant Amnestic Neurodegenerative Syndrome in Clinical Practice: Nick Corriveau-Lecavalier, PhD & David T. Jones, MD

A duo of experts from Mayo Clinic discussed how recent developments in clinical criteria for diagnosing limbic-predominant amnestic neurodegenerative syndrome allow for more accurate differentiation from Alzheimer disease. [WATCH TIME: 9 minutes]


Michael Hotchkin

Latest:

Unique Composition of CNM-Au8 to Treat MS and ALS: Michael Hotchkin

The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]

© 2024 MJH Life Sciences

All rights reserved.